UK Eli Lilly Foundayo Approval Makes Britain First In Europe To Clear New GLP-1 Pill

The UK Eli Lilly Foundayo approval has made Britain the first country in Europe to authorise the once-daily GLP-1 tablet for both weight management and type 2 diabetes.

The Medicines and Healthcare products Regulatory Agency (MHRA) confirmed on 10 August 2026 that it had authorised orforglipron, sold under the brand name Foundayo, following an assessment of its safety, quality and effectiveness.

The decision opens the door to a new oral alternative in a market that has become strongly associated with injectable GLP-1 medicines such as Mounjaro and Wegovy.

However, regulatory approval does not mean Foundayo is immediately available through the NHS. The MHRA has made clear that the tablet is not currently available on the health service, while NICE continues its assessment of the treatment for weight management.

What Has the UK Approved Foundayo For?

According to the MHRA’s official Foundayo authorisation announcement, orforglipron has been authorised for weight loss and weight maintenance alongside a reduced-calorie diet and increased physical activity.

For weight management, the approval covers UK adults with:

• a body mass index (BMI) of 30 or above; or
• a BMI between 27 and 30 together with at least one weight-related comorbidity.

The medicine has also been authorised to improve glycaemic control in people whose type 2 diabetes is insufficiently controlled.

This means Foundayo has secured a UK marketing authorisation for two significant areas of metabolic health, although individual patients will still need an appropriate clinical assessment and prescription.

It is a prescription-only medicine rather than a treatment that can legally be bought as an ordinary over-the-counter weight-loss product.

How Does Eli Lilly’s Foundayo Work?

Foundayo contains orforglipron, a GLP-1 receptor agonist.

GLP-1, or glucagon-like peptide-1, is a hormone naturally released by the body after eating. The MHRA says orforglipron acts on areas of the brain involved in appetite regulation, helping people feel fuller for longer while reducing hunger and food cravings.

For people with type 2 diabetes, it can also help reduce blood sugar levels when those levels are high.

One of the important differences between Foundayo and some established GLP-1 treatments is its format. It is taken as a tablet once a day rather than as a weekly injection.

The MHRA says it can be taken at any time of day without food or water restrictions. Treatment begins with a 0.8mg dose before progressing through higher dose strengths, with at least one month at each dose level.

That dosing flexibility could become an important point of competition as pharmaceutical companies expand beyond injectable obesity medicines.

Is Foundayo Available on the NHS?

Not yet.

This is one of the most important distinctions following the UK Eli Lilly Foundayo approval.

MHRA authorisation establishes that a medicine can be marketed for its authorised indications in the UK. It does not automatically mean the NHS will routinely fund or prescribe it for weight management.

The regulator specifically stated that Foundayo is not currently available via the NHS.

For weight management, the NICE appraisal of orforglipron remains in development. NICE is considering the clinical and cost effectiveness of the treatment within its marketing authorisation for adults living with obesity or overweight alongside a weight-related condition.

At the time of writing, NICE lists 18 November 2026 as the expected publication date for that appraisal. That timetable could still be subject to change.

The position on type 2 diabetes is different. NICE previously decided not to conduct a separate technology evaluation of orforglipron for that indication because its wider type 2 diabetes guidance already includes recommendations covering GLP-1 receptor agonists at class level.

Patients should therefore not interpret the MHRA announcement as confirmation that they can immediately request Foundayo through NHS weight-management services.

When Could Foundayo Become Available Privately?

Eli Lilly intends to introduce Foundayo in the UK private-prescription market later in August 2026, according to Reuters.

A company spokesperson told the news agency that the medicine would launch privately later this month. The spokesperson also said its private UK list price would be lower than Mounjaro’s listed £330 monthly price, although an exact Foundayo price was not disclosed.

Any private access would still require an appropriate prescription.

The MHRA stresses that all GLP-1 medicines are prescription-only and should be obtained from a registered pharmacy following prescribing by a doctor. It has also warned that purchasing GLP-1 products from unregulated sellers can carry serious health risks.

What Side Effects Has the MHRA Highlighted?

As with other medicines in the GLP-1 category, Foundayo can cause side effects.

The MHRA lists the most commonly reported effects associated with orforglipron as nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain.

The regulator has said it will continue monitoring the medicine’s safety and effectiveness after authorisation.

Anyone who believes they have experienced a suspected adverse reaction should speak to a doctor, pharmacist or nurse. Suspected medicine side effects can also be reported through the MHRA’s official Yellow Card safety reporting scheme.

The regulator is also due to publish the medicine’s full Summary of Product Characteristics and Patient Information Leaflet through the MHRA Products website within seven days of the approval.

Why Is the Foundayo Approval Significant for the UK?

The approval gives Britain another major oral GLP-1 option only two months after the MHRA authorised the tablet form of Novo Nordisk’s Wegovy for weight management in June 2026.

Foundayo therefore enters an increasingly competitive market in which pharmaceutical companies are seeking to offer alternatives to injectable treatments.

For London patients and healthcare providers, the immediate significance is primarily regulatory rather than an overnight change in NHS treatment.

Doctors now have another authorised medicine in the UK, but access, prescribing criteria and NHS funding remain separate questions.

The development also comes against the backdrop of closer cooperation between Eli Lilly and the UK government. The government’s Obesity Healthcare Goals programme says an agreement announced in October 2024 included plans for Lilly to invest £279 million in the UK and cooperate on approaches to obesity care.

That programme also includes work examining community-based obesity services and ways of reducing pressure on existing NHS pathways.

What Happens Next?

Attention will now turn to the commercial launch of Foundayo and, more importantly for NHS weight-management patients, NICE’s final recommendation.

Until NICE completes its appraisal, UK approval should not be confused with routine NHS availability.

The MHRA’s decision nevertheless represents a significant milestone for Eli Lilly. Britain is now the first European country to authorise Foundayo for both weight management and type 2 diabetes, adding another oral treatment to the rapidly developing GLP-1 market.

For patients considering GLP-1 treatment, decisions should be made with an appropriately qualified healthcare professional rather than on the basis of availability or weight-loss claims alone.